Cargando…

Tolerogenic vaccines for Multiple Sclerosis

Tolerogenic vaccines represent a new class of vaccine designed to re-establish immunological tolerance, restore immune homeostasis, and thereby reverse autoimmune disease. Tolerogenic vaccines induce long-term, antigen-specific, inhibitory memory that blocks pathogenic T cell responses via loss of e...

Descripción completa

Detalles Bibliográficos
Autores principales: Mannie, Mark D., Curtis, II, Alan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899137/
https://www.ncbi.nlm.nih.gov/pubmed/23357858
http://dx.doi.org/10.4161/hv.23685
_version_ 1782300526328676352
author Mannie, Mark D.
Curtis, II, Alan D.
author_facet Mannie, Mark D.
Curtis, II, Alan D.
author_sort Mannie, Mark D.
collection PubMed
description Tolerogenic vaccines represent a new class of vaccine designed to re-establish immunological tolerance, restore immune homeostasis, and thereby reverse autoimmune disease. Tolerogenic vaccines induce long-term, antigen-specific, inhibitory memory that blocks pathogenic T cell responses via loss of effector T cells and gain of regulatory T cell function. Substantial advances have been realized in the generation of tolerogenic vaccines that inhibit experimental autoimmune encephalomyelitis in a preclinical setting, and these vaccines may be a prequel of the tolerogenic vaccines that may have therapeutic benefit in Multiple Sclerosis. The purpose here is to provide a snapshot of the current concepts and future prospects of tolerogenic vaccination for Multiple Sclerosis, along with the central challenges to clinical application.
format Online
Article
Text
id pubmed-3899137
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-38991372014-02-03 Tolerogenic vaccines for Multiple Sclerosis Mannie, Mark D. Curtis, II, Alan D. Hum Vaccin Immunother Commentary Tolerogenic vaccines represent a new class of vaccine designed to re-establish immunological tolerance, restore immune homeostasis, and thereby reverse autoimmune disease. Tolerogenic vaccines induce long-term, antigen-specific, inhibitory memory that blocks pathogenic T cell responses via loss of effector T cells and gain of regulatory T cell function. Substantial advances have been realized in the generation of tolerogenic vaccines that inhibit experimental autoimmune encephalomyelitis in a preclinical setting, and these vaccines may be a prequel of the tolerogenic vaccines that may have therapeutic benefit in Multiple Sclerosis. The purpose here is to provide a snapshot of the current concepts and future prospects of tolerogenic vaccination for Multiple Sclerosis, along with the central challenges to clinical application. Landes Bioscience 2013-05-01 2013-01-28 /pmc/articles/PMC3899137/ /pubmed/23357858 http://dx.doi.org/10.4161/hv.23685 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Commentary
Mannie, Mark D.
Curtis, II, Alan D.
Tolerogenic vaccines for Multiple Sclerosis
title Tolerogenic vaccines for Multiple Sclerosis
title_full Tolerogenic vaccines for Multiple Sclerosis
title_fullStr Tolerogenic vaccines for Multiple Sclerosis
title_full_unstemmed Tolerogenic vaccines for Multiple Sclerosis
title_short Tolerogenic vaccines for Multiple Sclerosis
title_sort tolerogenic vaccines for multiple sclerosis
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899137/
https://www.ncbi.nlm.nih.gov/pubmed/23357858
http://dx.doi.org/10.4161/hv.23685
work_keys_str_mv AT manniemarkd tolerogenicvaccinesformultiplesclerosis
AT curtisiialand tolerogenicvaccinesformultiplesclerosis